CV Lattes
ResearcherID
ORCID
Instituto Butantan (Institutional affiliation from the last research proposal) Birthplace: Brazil
Bachelor in Chemistry at the Universidade Estadual de Campinas (1982) and a PhD in Biochemistry at the Universidade de São Paulo (1988). Has experience in Molecular Biotechnology, working in the following subjects: Vaccine development, recombinant BCG, pertussis, pneumococcus, tuberculosis and schistosoma. She is researcher at the Butantan Institute's Vaccine Development Laboratory (formerly Biotechnology Center). Has experience in Molecular Biotechnology, focusing on Vaccine Development, acting on the following subjects: recombinant BCG vaccines, pertussis, pneumococcus, tuberculosis and schistosoma. She has been Vice Director of Fundação Butantan (2005-2009), Director of the Center of Biotechnology (2010-2016) and of the Laboratory of Vaccine Development of Instituto Butantan (2016-2019) and Member of the Steering Committee of the Developing Countries Vaccine Manufacturing Network (DCVMN) (2006-2014), Comissão Técnica Nacional de Biossegurança (CTNBio) (2013-2019) and Comissão de Ética em Pesquisa com Seres Humanos do ICB -USP (2020-2023). Currently is member of the Academic Management Board of the LIVE-Leading International Vaccinology Education Course of Erasmus / European Union (2016- ), the Coalition for Epidemic Preparedness and Innovation (CEPI -2024- ) and RedeTB (Brazilian TB Network). (Source: Lattes Curriculum)
| Articles published in Pesquisa para Inovação FAPESP about the researcher: |
| FAPESP-funded startups are developing COVID-19 vaccines |
| More itemsLess items |
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Projects developed by the Vaccine Development Laboratory and associated laboratories, including external laboratories, often involve the use of GMOs and/or transgenic/immunodeficient animals in different phases of research. In this context, the acquisition of new equipment and improvements to the infrastructure for access to classified areas will have a direct and significant impact on ma…
Our studies have demonstrated the advantages of Mycobacterium bovis BCG as an antigen presenting system in the development of new vaccines. The project aims to expand the use of methods of heterologous gene expression in BCG developed in our laboratories with the aim of proposing new vaccines in the immunization against Pertussis, Tuberculosis, Pneumococcus and Schistosome, and to improve…
(Only some records are available in English at this moment)
Bacillus Calmette and Guérin (BCG) is a widely used live attenuated vaccine against tuberculosis (TB). However, its efficacy in preventing pulmonary TB in adults is limited and variable. Gene editing in BCG has enabled advances in the study of immune response evasion mechanisms and in the development of new vaccines. The CRISPR/Cas9 tool, with its great biotechnological potential, allows …
The vaccines currently in use against the SARS-CoV-2 coronavirus were developed based on both traditional processes and more modern technologies such as viral vectors and RNA-based vaccines. These new strategies were very effective and safe in clinical trials and have shown great efficiency in the control of COVID-19. These approaches take into account the presentation of important antige…
(Only some records are available in English at this moment)
Tuberculosis (TB) is a global health burden. Besides the public health issue, the disease is also an economic problem in livestock production. Vaccination is the most cost effective strategy for TB control. So far, the only licensed vaccine is BCG, a live attenuated strain of Mycobacterium bovis. Although it carries several advantages, BCG protection declines over time, ranging from 0-80%…
Tuberculosis (TB) was responsible for more than 10.4 million cases and 1.8 million deaths in 2015. This is primarily because the only available vaccine, BCG, fails to reduce TB incidence sufficiently, there is a lack of biomarkers of protection and of biomarkers predicting treatment outcome, and there is a rising frequency of multi drug-resistant (MDR) Mycobacterium tuberculosis (Mtb) str…